Article Text

PDF
Interferon γ-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFα therapy
  1. Kay Greveson,
  2. Charlie Murray,
  3. Christos Toumpanakis,
  4. Owen Epstein,
  5. Mark Hamilton,
  6. Marc Lipman
  1. Centre for Gastroenterology, Royal Free Hospital, London, UK
  1. Correspondence to Ms Kay Greveson, Centre for Gastroenterology, Royal Free Hospital, Pond St, London NW3 2QG, UK; kay.greveson{at}royalfree.nhs.uk

Abstract

Screening for, and treatment of, latent tuberculosis infection (LTBI) before anti- tumour necrosis factor α therapy has been shown to decrease the incidence of active tuberculosis by more than 80% and is recommended before initiation of treatment. In the absence of a ‘gold standard’ test for LTBI, current screening involves taking a clinical history of risk factors, chest radiograph and tuberculin skin test. Alternative cellular immune-based screening tests have been developed to detect Mycobacterium tuberculosis infection. This paper summarises the current position and advances in the use of newer screening strategies for LTBI.

Statistics from Altmetric.com

Footnotes

  • Competing Interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.